Neurocrine Biosciences, Inc.

Mycovia Pharmaceuticals, Inc.

Spero Therapeutics, Inc.

Biogen, Incorporated

Medivir Ab

Evolva Sa

Viamet Pharmaceuticals, Inc.

Medivation Technologies, Inc.

Thierry Bonnaud

Andrew Carr

William Joel Hoekstra

David Dale Wirth

Richard Edwards

Scott E Zook

Kevin McGee

Tracy Ehiwe

Akash Jain

Bin-Feng Li

Evan Hecker

Urszula Grabowska

Jussi J Kangasmetsa

Magnus Nilsson

Xiao-Xiong Zhou

Tony Johnson

Lourdes Salvador Oden

Prathama Satyendra Mainkar

Bjorn Olof Classon

David R Witty

Alexandra Santana Sorensen

Peteris Alberts

David T MacPherson

Jean-Philippe Meyer

Melya Hughes Crameri

David Pearson

Laia Crespo

Victor Diaz

Matt Tozer

Mark Liley

Philip Jackson

Rolf Noren

Joanne Kelleher

Michael Williams

Osama Suleiman

Gerard M Giblin

Philip Fallon

Mark Henderson

Scott Zook

Kevin Mcgee

Mainkar S Prathama

Olivier Lambert

Colm Campbell

Nico Bauer

The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

The invention relates to a novel process for preparing Spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.

Process for preparing spiro derivatives

Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.

Valbenazine salts and polymorphs thereof

Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]-isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.

Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.

The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for preparing polymorphs of compound 1 and substituted derivatives thereof.

Antifungal compounds and processes for making

Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases. 

Substituted 1,3-dioxanes useful as PPAR modulators

Cysteine protease inhibitors

Growing community of inventors

Cambridge, United Kingdom

Thierry Bonnaud